122 related articles for article (PubMed ID: 38357002)
1. Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity.
Kang N; Ma J; Hu Y; Di R; Wang L; Zhang X; Lai Y; Liu Y
Pharmaceuticals (Basel); 2024 Feb; 17(3):. PubMed ID: 38543077
[TBL] [Abstract][Full Text] [Related]
2. Targeting the nucleic acid oxidative damage repair enzyme MTH1: a promising therapeutic option.
Ding Y; Liu Q
Front Cell Dev Biol; 2024; 12():1334417. PubMed ID: 38357002
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of MTH1 inhibition-induced DNA strand breaks: The slippery slope from the oxidized nucleotide pool to genotoxic damage.
Rai P; Sobol RW
DNA Repair (Amst); 2019 May; 77():18-26. PubMed ID: 30852368
[TBL] [Abstract][Full Text] [Related]
4. Targeting human MutT homolog 1 (MTH1) for cancer eradication: current progress and perspectives.
Yin Y; Chen F
Acta Pharm Sin B; 2020 Dec; 10(12):2259-2271. PubMed ID: 33354500
[TBL] [Abstract][Full Text] [Related]
5. MTH1 as a Chemotherapeutic Target: The Elephant in the Room.
Samaranayake GJ; Huynh M; Rai P
Cancers (Basel); 2017 May; 9(5):. PubMed ID: 28481306
[TBL] [Abstract][Full Text] [Related]
6. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
[TBL] [Abstract][Full Text] [Related]
7. Integration of Activation by Hypoxia and Inhibition Resistance of Tumor Cells to Apoptosis for Precise and Augmented Photodynamic Therapy.
Shao Y; Chen M; Chen W; Wang Z; Sui M; Tian M; Wu Y; Song J; Ji D; Song F
Adv Healthc Mater; 2023 Oct; 12(25):e2300503. PubMed ID: 37306493
[TBL] [Abstract][Full Text] [Related]
8. Light-Elicited and Oxygen-Saved Iridium Nanocapsule for Oxidative Damage Intensified Oncotherapy.
Chen G; Wang X; He Z; Li X; Yang Z; Zhang Y; Li Y; Zheng L; Miao Y; Zhang D
Molecules; 2023 May; 28(11):. PubMed ID: 37298873
[TBL] [Abstract][Full Text] [Related]
9. Advances in immunotherapy for glioblastoma multiforme.
Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
Front Immunol; 2022; 13():944452. PubMed ID: 36311781
[TBL] [Abstract][Full Text] [Related]
10. miR-4478 Accelerates Nucleus Pulposus Cells Apoptosis Induced by Oxidative Stress by Targeting MTH1.
Zhang J; Liu R; Mo L; Liu C; Jiang J
Spine (Phila Pa 1976); 2023 Mar; 48(5):E54-E69. PubMed ID: 36130054
[TBL] [Abstract][Full Text] [Related]
11. Platinum-based nanocomposites loaded with MTH1 inhibitor amplify oxidative damage for cancer therapy.
Song Q; Yang W; Deng X; Zhang Y; Li J; Xing X; Chen W; Liu W; Hu H; Zhang Y
Colloids Surf B Biointerfaces; 2022 Oct; 218():112715. PubMed ID: 35932557
[TBL] [Abstract][Full Text] [Related]
12. Targeting the DNA repair enzymes MTH1 and OGG1 as a novel approach to treat inflammatory diseases.
Karsten S
Basic Clin Pharmacol Toxicol; 2022 Aug; 131(2):95-103. PubMed ID: 35708697
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
